Search Within

Advanced Practice Providers

  1. "Steven Horwitz"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (11)
Groups
  1. Center for Hematologic Malignancies (43)
  2. Department of Medicine (43)
  3. Hematologic Malignancies, Division of (43)
  4. Lymphoma (43)
  5. Population Sciences Research Program (43)
  6. Survivorship Research (29)

More Groups

People
  1. Steven Horwitz (43)
  2. Alison Moskowitz (41)
  3. Ariela Noy (31)
  4. Andrew Zelenetz (30)
  5. David Straus (27)
  6. Maria Palomba (26)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (4)
  4. 2022 (1)
  5. 2021 (6)
  6. 2020 (4)

More Years

Publications
  1. Blood (22)
  2. Journal of Clinical Oncology (7)
  3. Hematological Oncology (5)
  4. Annals of Oncology (2)
  5. American Journal of Hematology (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. American Society of Clinical Oncology (7)
  3. Wiley Blackwell (5)
  4. Nature Publishing Group (2)
  5. Oxford University Press (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: A phase 1b/2a trial
    Journal Article

    Horwitz, S. M.; Nirmal, A. J.; Rahman, J.; Xu, R.; Drill, E.; Galasso, N.; Ganesan, N.; Davey, T.; Hancock, H.; Perez, L.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save